Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure.
BCG-unresponsive
Bladder cancer
Chemohyperthermia
Cystectomy
Progression
Recurrence
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
04
01
2023
accepted:
07
02
2023
medline:
9
11
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
To evaluate hyperthermic intravesical chemotherapy (HIVEC) efficacy regarding 1-year disease-free survival (RFS) rate and bladder preservation rate in patients with non-muscle invasive bladder cancer (NMIBC) who fail bacillus Calmette-Guérin (BCG) therapy. This is a multicenter retrospective series from a national database (7 expert centers). Between January 2016 and October 2021, patients treated with HIVEC for NMIBC who failed BCG have been included in our study. These patients had a theoretical indication for cystectomy but were ineligible for surgery or refused it. A total of 116 patients treated with HIVEC and with a follow-up > 6 months were included in this study and retrospectively analyzed. The median follow-up was 20.6 months. The 12 month-RFS (recurrence-free survival) rate was 62.9%. The bladder preservation rate was 87.1%. Fifteen patients (12.9%) progressed to muscle infiltration, three of them having a metastatic disease at the time of progression. Predictive factors of progression were T1 stage, high grade and very high-risk tumors according to the EORTC classification. Chemohyperthermia using HIVEC achieved an RFS rate of 62.9% at 1 year and enabled a bladder preservation rate of 87.1%. However, the risk of progression to muscle-invasive disease is not negligible, particularly for patients with very high-risk tumors. In these patients who fail BCG, cystectomy should remain the standard of care and HIVEC may be discussed cautiously for patients who are not eligible for surgery and well informed of the risk of progression.
Identifiants
pubmed: 36811732
doi: 10.1007/s00345-023-04332-z
pii: 10.1007/s00345-023-04332-z
doi:
Substances chimiques
BCG Vaccine
0
Adjuvants, Immunologic
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3195-3203Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Witjes JA (2006) Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49(5):790–797. https://doi.org/10.1016/j.eururo.2006.01.017
doi: 10.1016/j.eururo.2006.01.017
pubmed: 16464532
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL et al (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ). Eur Urol 81(1):75–94. https://doi.org/10.1016/j.eururo.2021.08.010
doi: 10.1016/j.eururo.2021.08.010
pubmed: 34511303
van der Heijden AG, Verhaegh G, Jansen CFJ, Schalken JA, Witjes JA (2015) Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 173(4):1375–1380. https://doi.org/10.1097/01.ju.0000146274.85012.e1
doi: 10.1097/01.ju.0000146274.85012.e1
Arends TJH, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F et al (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non–muscle-invasive bladder cancer. Eur Urol 69(6):1046–1052. https://doi.org/10.1016/j.eururo.2016.01.006
doi: 10.1016/j.eururo.2016.01.006
pubmed: 26803476
Tan WS, Panchal A, Buckley L, Devall AJ, Loubière LS, Pope AM et al (2019) Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette-Guérin therapy (HYMN): a phase III, open-label. Randomised Controlled Trial Eur Urol 75(1):63–71. https://doi.org/10.1016/j.eururo.2018.09.005
doi: 10.1016/j.eururo.2018.09.005
pubmed: 30274699
Sousa A, Piñeiro I, Rodríguez S, Aparici V, Monserrat V, Neira P et al (2016) Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate–high-risk non-muscle-invasive bladder cancer. Int J Hyperthermia 32(4):374–380. https://doi.org/10.3109/02656736.2016.1142618
doi: 10.3109/02656736.2016.1142618
pubmed: 26915466
de Jong JJ, Hendricksen K, Rosier M, Mostafid H, Boormans JL (2018) Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. Bladder Cancer 4(4):395–401. https://doi.org/10.3233/blc-180191
doi: 10.3233/blc-180191
pubmed: 30417050
pmcid: 6218110
Tan WS, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P et al (2022) Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label. Randomised Controlled Trial Eur Urol S0302–2838(22):02552. https://doi.org/10.1016/j.eururo.2022.08.003
doi: 10.1016/j.eururo.2022.08.003
Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M et al (2016) Definitions, end points, and clinical trial designs for non–muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol 34(16):1935–1944. https://doi.org/10.1200/jco.2015.64.4070
doi: 10.1200/jco.2015.64.4070
pubmed: 26811532
pmcid: 5321095
Irani J (2016) Intravesical instillations in non-muscle-invasive bladder cancer (NMIBC). Prospects for thermochemotherapy. Prog Urol 6(14):860–864. https://doi.org/10.1016/j.purol.2016.09.057
doi: 10.1016/j.purol.2016.09.057
Nouhaud FX, Chakroun M, Lenormand C, Ouzaid I, Peyronnet B, Gryn A et al (2021) Comparison of the prognosis of primary vs. progressive muscle invasive bladder cancer after radical cystectomy: results from a large multicenter study. Urol Oncol 39(3):195.e1-195.e6. https://doi.org/10.1016/j.urolonc.2020.09.006
doi: 10.1016/j.urolonc.2020.09.006
pubmed: 33214030
Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M et al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 22(7):919–930. https://doi.org/10.1016/S1470-2045(21)00147-9
doi: 10.1016/S1470-2045(21)00147-9
pubmed: 34051177
García-Perdomo HA, Sánchez AL, Spiess PE (2022) Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review. Urol Oncol 40(9):409.e1-409.e8. https://doi.org/10.1016/j.urolonc.2022.02.003
doi: 10.1016/j.urolonc.2022.02.003
pubmed: 35232680
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM et al (2021) Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 22(1):107–117. https://doi.org/10.1016/S1470-2045(20)30540-4
doi: 10.1016/S1470-2045(20)30540-4
pubmed: 33253641
Packiam VT, Richards J, Schmautz M, Heidenreich A, Boorjian SA (2021) The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol 31(3):178–187. https://doi.org/10.1097/MOU.0000000000000863
doi: 10.1097/MOU.0000000000000863
pubmed: 33742981
Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E et al (2021) Phase I trial of N-803, an Il15 receptor agonist, with rituximab in patients with indolent non-hodgkin lymphoma. Clin Cancer Res 27(12):3339–3350. https://doi.org/10.1158/1078-0432.CCR-20-4575
doi: 10.1158/1078-0432.CCR-20-4575
pubmed: 33832946
pmcid: 8197753
Kamat AM, Lerner SP, O’Donnell M, Georgieva MV, Yang M, Inman BA et al (2020) Evidence-based assessment of current and emerging bladder-sparing therapies for non–muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy: a systematic review and meta-analysis. Eur Urol Oncol 3(3):318–340. https://doi.org/10.1016/j.euo.2020.02.006
doi: 10.1016/j.euo.2020.02.006
pubmed: 32201133
Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H (2007) Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52(4):1123–1129. https://doi.org/10.1016/j.eururo.2007.02.063
doi: 10.1016/j.eururo.2007.02.063
pubmed: 17383080